![Amy Chappell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Amy Chappell
Direttore/Membro del Consiglio presso
BIOVIE INC.
Patrimonio netto: 1 105 $ in data 30/09/2026
Profilo
Amy S.
Chappell is currently an Independent Director at BioVie, Inc. since 2025 and Chief Medical Officer at Solaxa, Inc. since 2024.
Formerly, Dr. Chappell was Chief Medical Officer at Climb Bio, Inc. from 2020 to 2021.
Education includes undergraduate studies at Antioch College and a doctorate from The Indiana University School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
BIOVIE INC. CLASS A 0,01% | 31/08/2026 | 727 ( 0,01% ) | 1 105 $ | 30/09/2026 |
Posizioni attive di Amy Chappell
| Società | Posizione | Inizio |
|---|---|---|
| BIOVIE INC. | Direttore/Membro del Consiglio | 22/07/2025 |
Precedenti posizioni note di Amy Chappell
| Società | Posizione | Fine |
|---|---|---|
| CLIMB BIO, INC. | Direttore Tecnico/Scientifico/R&S | 31/12/2021 |
Formazione di Amy Chappell
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
20
Relazioni di 1° grado
4
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
BioVie, Inc.
 BioVie, Inc. BiotechnologyHealth Technology Develops drug therapies for chronic debilitating conditions | Health Technology |
Antioch College
 Antioch College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Indiana University School of Medicine
 The Indiana University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
